Literature DB >> 18464946

Dilated cardiomyopathy and left bundle branch block associated with ingestion of colloidal gold and silver is reversed by British antiLewisite and vitamin E: the potential toxicity of metals used as health supplements.

Stephen Lawrence Archer1.   

Abstract

A case of left bundle branch block and a dilated, nonhypertrophic cardiomyopathy associated with ingestion of colloidal gold and silver as an 'energy tonic' is described. The cardiac disease was reversed within two months by a course of dimercaprol (Akorn Inc, USA) (British antiLewisite) and vitamin E. This is the first case of gold and silver cardiomyopathy in humans, and highlights the risks of these colloidal metal 'health supplements'.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18464946      PMCID： PMC2643143          DOI： 10.1016/s0828-282x(08)70604-4

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN： 0828-282X            Impact factor:   5.223


  9 in total

1.  METABOLISM, TOXICITY AND MANNER OF ACTION OF GOLD COMPOUNDS USED IN THE TREATMENT OF ARTHRITIS. I. HUMAN PLASMA AND SYNOVIAL FLUID CONCENTRATION AND URINARY EXCRETION OF GOLD DURING AND FOLLOWING TREATMENT WITH GOLD SODIUM THIOMALATE, GOLD SODIUM THIOSULFATE, AND COLLOIDAL GOLD SULFIDE.

Authors:  R H Freyberg; W D Block; S Levey
Journal:  J Clin Invest       Date:  1941-07       Impact factor: 14.808

2.  Use of complementary and alternative medicine by persons with arthritis: results of the National Health Interview Survey.

Authors:  Sara A Quandt; Haiying Chen; Joseph G Grzywacz; Ronny A Bell; Wei Lang; Thomas A Arcury
Journal:  Arthritis Rheum       Date:  2005-10-15

3.  In vivo and in vitro cardiotoxicity of a gold-containing antineoplastic drug candidate in the rabbit.

Authors:  G D Hoke; R A Macia; P C Meunier; P J Bugelski; C K Mirabelli; G F Rush; W D Matthews
Journal:  Toxicol Appl Pharmacol       Date:  1989-09-01       Impact factor: 4.219

4.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

Authors:  M R Bristow; E M Gilbert; W T Abraham; K F Adams; M B Fowler; R E Hershberger; S H Kubo; K A Narahara; H Ingersoll; S Krueger; S Young; N Shusterman
Journal:  Circulation       Date:  1996-12-01       Impact factor: 29.690

5.  British anti-Lewisite (dimercaprol): an amazing history.

Authors:  Joel A Vilensky; Kent Redman
Journal:  Ann Emerg Med       Date:  2003-03       Impact factor: 5.721

6.  Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative.

Authors:  Maria Pia Rigobello; Guido Scutari; Rita Boscolo; Alberto Bindoli
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

7.  Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction.

Authors:  R E Foster; D B Johnson; F Barilla; G G Blackwell; R Orr; M Roney; A W Stanley; G M Pohost; L J Dell'Italia
Journal:  Am Heart J       Date:  1998-08       Impact factor: 4.749

8.  Auranofin increases apoptosis and ischaemia-reperfusion injury in the rat isolated heart.

Authors:  Kylie Venardos; Glenn Harrison; John Headrick; Anthony Perkins
Journal:  Clin Exp Pharmacol Physiol       Date:  2004 May-Jun       Impact factor: 2.557

9.  Induction of lesions of selenium-vitamin E deficiency in pigs fed silver.

Authors:  J F Van Vleet
Journal:  Am J Vet Res       Date:  1976-12       Impact factor: 1.156
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.